Where Chinese Investors Meet Global Investment News and Opportunities


Shenzhen BioScien Acquires China Rights to Generex Cancer Vaccine

Shenzhen BioScien in-licensed greater China rights to an immunotherapeutic vaccine for prostate cancer from Generex Biotech of the US in a $5 million agreement. In a Phase I trial, conducted by Generex’s subsidiary Antigen Express, AE37 produced an activation of T cells in patients with prostate cancer. Generex said the activation was robust, long-term, and specific. BioScien will develop the drug for mainland China plus Taiwan, Hong Kong and Macau.

Source: China Biotoday

Do NOT follow this link or you will be banned from the site!